Combined effects of a factor Xa inhibitor YM466 and a GPIIb/IIIa antagonist YM128 on thrombosis and neointima formation in mice

Summary

Thrombosis and neointima formation limit the efficacy of coronary angioplasty. Factor Xa inhibitors and GPIIb/IIIa antagonists have shown to be effective on acute thrombosis and late neointima formation, however, their combined effects remain to be elucidated. Vascular injury was induced by FeCl₃ in the carotid artery in mice. For thrombosis studies, the test drug was orally administered 1 hour before vascular injury. For neointima studies, the test drug was orally administered 1 hour before and twice daily for 1 week after vascular injury, and then histological analysis was performed 3 weeks after vascular injury. YM466 inhibited thrombotic occlusion at 30 mg/kg with prolongation of prothrombin time (PT), and tail transection bleeding time (BT) was affected at 100 mg/kg. YM466 also inhibited neointima formation at 10 mg/kg. YM128 inhibited thrombotic occlusion and neointima formation at 10 and 30 mg/kg, respectively, with inhibition of platelet aggregation and prolongation of BT. In contrast, the combination of 10 mg/kg YM466 and 3 mg/kg YM128 inhibited thrombotic occlusion and neointima formation without affecting PT, platelet aggregation and BT. Concomitant inhibition of factor Xa and GPIIb/IIIa may provide a safer and more effective therapeutic regimen for treatment of coronary angioplasty.

Keywords

Combination - factor Xa inhibitor - GPIIb/IIIa antagonist - thrombosis - neointima formation

^* Yoshiyuki Iwatsuki and Tomihisa Kawasaki contributed equally to this work.

• References

• 1 Harding SA, Walters DL, Palacios IF. et al. Adjunctive pharmacotherapy for coronary stenting. Curr Opin Cardiol 2001; 16: 293-9.
• 2 Peters RJ, Mehta SR, Fox KA. et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003; 108: 1682-7.
• 3 Elodi S, Varadi K. Optimization of conditions for the catalytic effect of the factor IXa-factor VIII complex: probable role of the complex in the amplification of blood coagulation. Thromb Res 1979; 15: 617-29.
• 4 Nicholson AC, Nachman RL, Altieri DC. et al. Effector cell protease receptor-1 is a vascular receptor for coagulation factor Xa. J Biol Chem 1996; 271: 28407-13.
• 5 Pruitt JR, Pinto DJ, Galemmo Jr RA. et al. Discovery of 1-(2-aminomethylphenyl)-3- trifluoromethyl-N-[3-fluoro-2’-(aminosulfonyl)[1,1’-biphenyl]]-4-yl]-1H-pyrazole-5- carboxyamide (DPC602), a potent, selective, and orally bioavailable factor Xa inhibitor (1). J Med Chem 2003; 46: 5298-315.
• 6 Rebello SS, Bentley RG, Morgan SR. et al. Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis. Br J Pharmacol 2001; 133: 1190-8.
• 7 Kaiser B, Paintz M, Scholz O. et al. A synthetic inhibitor of factor Xa, DX-9065a, reduces proliferation of vascular smooth muscle cells in vivo in rats. Thromb Res 2000; 98: 175-85.
• 8 Schwartz RS, Holder DJ, Holmes DR. et al. Neointimal thickening after severe coronary artery injury is limited by a short-term administration of a factor Xa inhibitor. Results in a porcine model. Circulation 1996; 93: 1542-8.
• 9 Dyke CK, Becker RC, Kleiman NS. et al. First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation. Circulation 2002; 105: 2385-91.
• 10 Tan KT, Makin A, Lip GY. Factor X inhibitors. Expert Opin Investig Drugs 2003; 12: 799-804.
• 11 Pakala R, Willerson JT, Benedict CR. Effect of serotonin, thromboxane A2, and specific receptor antagonists on vascular smooth muscle cell proliferation. Circulation 1997; 96: 2280-6.
• 12 Damiano BP, Mitchell JA, Giardino E. et al. Antiplatelet and antithrombotic activity of RWJ-53308, a novel orally active glycoprotein IIb/IIIa antagonist. Thromb Res 2001; 104: 113-26.
• 13 Chico TJ, Chamberlain J, Gunn J. et al. Effect of selective or combined inhibition of integrins α_IIbβ₃ and α_vβ₃ on thrombosis and neointima after oversized porcine coronary angioplasty. Circulation 2001; 103: 1135-41.
• 14 Neumann FJ, Kastrati A, Schmitt C. et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol 2000; 35: 915-21.
• 15 Gibson CM, Goel M, Murphy SA. et al. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. Global impairment of coronary blood flow in the setting of acute coronary syndromes (a RESTORE substudy). Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. Am J Cardiol 2000; 86: 1375-7 A5.
• 16 Lefkovits J, Ivanhoe RJ, Califf RM. et al. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators. Am J Cardiol 1996; 77: 1045-51.
• 17 Boersma E, Harrington RA, Moliterno DJ. et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002; 359: 189-98.
• 18 Simoons ML. GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 2001; 357: 1915-24.
• 19 Taniuchi Y, Sakai Y, Hisamichi N. et al. Biochemical and pharmacological characterization of YM-60828, a newly synthesized and orally active inhibitor of human factor Xa. Thromb Haemost 1998; 79: 543-8.
• 20 Moritani Y, Sato K, Shigenaga T. et al. Pharmacological properties of YM-57029, a novel platelet glycoprotein IIb/IIIa antagonist. Eur J Pharmacol 2002; 439: 43-52.
• 21 Suzuki K, Moritani Y, Hisamichi N. et al. Pharmacodynamics and pharmacokinetics of YM128, a GPIIb/IIIa antagonist prodrug. Drug Dev Res 2002; 55: 149-61.
• 22 Sato K, Kawasaki T, Hisamichi N. et al. Antithrombotic effects of YM-60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time. Br J Pharmacol 1998; 123: 92-6.
• 23 Fay WP, Parker AC, Ansari MN. et al. Vitronectin inhibits the thrombotic response to arterial injury in mice. Blood 1999; 93: 1825-30.
• 24 Kurz KD, Main BW, Sandusky GE. Rat model of arterial thrombosis induced by ferric chloride. Thromb Res 1990; 60: 269-80.
• 25 Kunsch C, Medford RM. Oxidative stress as a regulator of gene expression in the vasculature. Circ Res 1999; 85: 753-66.
• 26 Carmeliet P, Moons L, Stassen JM. et al. Vascular wound healing and neointima formation induced by perivascular electric injury in mice. Am J Pathol 1997; 150: 761-76.
• 27 Konstantinides S, Schafer K, Thinnes T. et al. Plasminogen activator inhibitor-1 and its cofactor vitronectin stabilize arterial thrombi after vascular injury in mice. Circulation 2001; 103: 576-83.